Preclinical Efficacy and Mechanisms of Mesenchymal Stem Cells in Animal Models of Autoimmune Diseases
Immune Network
;
: 81-88, 2014.
Article
in English
| WPRIM
| ID: wpr-121974
ABSTRACT
Mesenchymal stem cells (MSCs) are present in diverse tissues and organs, including bone marrow, umbilical cord, adipose tissue, and placenta. MSCs can expand easily in vitro and have regenerative stem cell properties and potent immunoregulatory activity. They inhibit the functions of dendritic cells, B cells, and T cells, but enhance those of regulatory T cells by producing immunoregulatory molecules such as transforming growth factor-beta, hepatic growth factors, prostaglandin E2, interleukin-10, indolamine 2,3-dioxygenase, nitric oxide, heme oxygenase-1, and human leukocyte antigen-G. These properties make MSCs promising therapeutic candidates for the treatment of autoimmune diseases. Here, we review the preclinical studies of MSCs in animal models for systemic lupus erythematosus, rheumatoid arthritis, Crohn's disease, and experimental autoimmune encephalomyelitis, and summarize the underlying immunoregulatory mechanisms.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Placenta
/
Arthritis, Rheumatoid
/
Autoimmune Diseases
/
Stem Cells
/
Umbilical Cord
/
Bone Marrow
/
Dendritic Cells
/
B-Lymphocytes
/
T-Lymphocytes
/
Dinoprostone
Type of study:
Prognostic study
Limits:
Humans
Language:
English
Journal:
Immune Network
Year:
2014
Type:
Article
Similar
MEDLINE
...
LILACS
LIS